Scholarlink

Background <p>Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used worldwide for its cardiometabolic benefits. However, it has recently been associated with nonarteritic anterior ischemic optic neuropathy (NAION). This report presents four clinical cases and explores a possible association.</p> Case presentation <p>Four male patients were diagnosed with NAION during semaglutide treatment, with treatment durations of less than one year in three cases. All presented with significant optic disc edema and intraretinal fluid on optical coherence tomography, along with crowded optic disc and small Bruch’s membrane opening diameters (&lt; 1.4&#xa0;mm in three cases). One patient exhibited optic disc drusen. Visual field defects corresponded with ganglion cell layer atrophy on optical coherence tomography. Systemic risk factors varied; two patients had only obesity.</p> Conclusions <p>Our observation suggests that individuals with small Bruch’s membrane opening diameter may be at risk of developing NAION during semaglutide treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月14日

查看全文
  • Hamid Ahmadi,
  • Steffen Hamann

摘要

Background

Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used worldwide for its cardiometabolic benefits. However, it has recently been associated with nonarteritic anterior ischemic optic neuropathy (NAION). This report presents four clinical cases and explores a possible association.

Case presentation

Four male patients were diagnosed with NAION during semaglutide treatment, with treatment durations of less than one year in three cases. All presented with significant optic disc edema and intraretinal fluid on optical coherence tomography, along with crowded optic disc and small Bruch’s membrane opening diameters (< 1.4 mm in three cases). One patient exhibited optic disc drusen. Visual field defects corresponded with ganglion cell layer atrophy on optical coherence tomography. Systemic risk factors varied; two patients had only obesity.

Conclusions

Our observation suggests that individuals with small Bruch’s membrane opening diameter may be at risk of developing NAION during semaglutide treatment.